RenovoRx to launch post-marketing registry study for cancer device

MOUNTAIN VIEW, Calif. - RenovoRx, Inc. (NASDAQ:RNXT), a $46.5 million market cap medical device company with a "FAIR" overall financial health rating according to InvestingPro, announced Monday the launch of its PanTheR Post-Marketing Registry Study to collect additional safety and performance data on its FDA-cleared RenovoCath drug-delivery device in patients with solid tumors.

Patient enrollment is expected to begin before the end of September 2025, with several cancer centers set to participate in the multi-center observational study. The University of Vermont Cancer Center will be the first clinical site to initiate enrollment, with Dr. Conor O’Neill serving as Principal Investigator. Analysts project a 36% revenue growth for RenovoRx in the current fiscal year, though InvestingPro data indicates the company is currently not profitable.

The PanTheR study aims to evaluate the long-term safety and survival outcomes for patients diagnosed with solid tumors who are treated using RenovoCath for targeted drug delivery. According to the company, participating cancer centers will purchase RenovoCath devices for use in the study.

"By gathering real-world data across diverse cancer types and clinical environments, PanTheR aims to advance innovation and inform evidence-based treatment strategies," said Leesa Gentry, Chief Clinical Officer of RenovoRx.

RenovoCath is a patented device intended for the isolation of blood flow and delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. It is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

The company is separately evaluating a drug-device combination product candidate in its ongoing Phase III TIGeR-PaC trial, which pairs the RenovoCath device with intra-arterial gemcitabine for pancreatic cancer treatment.

RenovoRx began commercializing the RenovoCath device in December 2024, receiving its first commercial purchase orders and subsequent repeat orders from several medical institutions, including National Cancer Institute-designated centers.

This article is based on a press release statement from RenovoRx.

In other recent news, RenovoRx Inc. reported its financial results for the first quarter of 2025, revealing revenue of $200,000 from its Renovocath device, which exceeded internal expectations. The company is optimistic about its growth prospects, despite increased expenses, due to ongoing clinical trials and strategic initiatives. Ascendiant Capital has raised its price target for RenovoRx stock to $11.50 from $11.00, maintaining a Buy rating. This adjustment reflects the analysts’ confidence in the company’s potential growth, based on a net present value analysis. Additionally, RenovoRx held its 2025 annual meeting of stockholders, where all nominated directors were elected for one-year terms. The elected directors include Shaun R. Bagai, Ramtin Agah, M.D., Kirsten Angela Macfarlane, Laurence J. Marton, M.D., Una S. Ryan, O.B.E., Ph.D., D.Sc., and Robert J. Spiegel, M.D., FACP. Shareholders also approved amendments to the company’s incentive plan. These developments highlight the company’s ongoing strategies and investor confidence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.